Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hydrobromide of vortioxetine

A compound, crystallization technology, used in the treatment of depression, especially adult major depression drugs, inhibitors of serotonin transporter, crystallization of the drug, 1-[2-phenyl]piperazine hydrobromide in the field of drugs, able to solve problems such as SSRI blockage

Active Publication Date: 2014-10-29
BEIJING LABWORLD BIO MEDICINE TECH
View PDF11 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, therapeutic use of SSRIs is hampered by the large number of non-responders, ie patients who do not respond or respond to SSRI therapy to a limited extent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hydrobromide of vortioxetine
  • Hydrobromide of vortioxetine
  • Hydrobromide of vortioxetine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0239] Embodiment 1: Preparation of the crystallization (B crystal form) of the compound of formula I

[0240] (1) Dissolve 8 g of vortioxetine free base in toluene, add 1 equivalent of hydrobromic acid (48% hydrobromic acid aqueous solution), stir and crystallize, and filter the precipitate to obtain vortioxetine hydrobromic acid Salt (93%);

[0241] (2) Put 10 g of the product obtained in step (1) into a three-necked flask, add 100 g of toluene and 10 g of water, heat to 85 ° C and stir to dissolve, cool and crystallize, and dry the filtered crystals at 60-70 ° C to obtain hydrogen Vortioxetine bromate (90%);

[0242] (3) Put 1 g of the product obtained in step (2) into a three-necked flask, add 12 g of acetone, stir at 55-60° C. for 30 minutes to form a slurry, then stir at room temperature for 1.5 hours, filter, and vacuum-dry the obtained crystals to obtain It is a crystal of the B crystal form.

[0243] The powder X-ray diffraction figure of above-mentioned step (3)...

Embodiment 2

[0244] Embodiment 2: Preparation of the crystallization (B crystal form) of the compound of formula I

[0245] (1) Dissolve 8 g of vortioxetine free base in toluene, add 1.05 equivalents of hydrobromic acid (47% hydrobromic acid aqueous solution), stir and crystallize, and filter the precipitate to obtain vortioxetine hydrobromic acid Salt (91%);

[0246] (2) Put 10 g of the product obtained in step (1) into a three-necked flask, add 80 g of toluene and 8 g of water, heat to 85 ° C and stir to dissolve, cool and crystallize, and dry the filtered crystals at a temperature of 60-70 ° C to obtain hydrogen Vortioxetine bromate (92%);

[0247] (3) Put 1 g of the product obtained in step (2) into a three-necked flask, add 10 g of acetone, stir at 55-60 ° C for 20 min to form a slurry, then stir at room temperature for 1 hour, filter, and vacuum-dry the obtained crystals to obtain It is a crystal of the B crystal form.

[0248] The powder X-ray diffraction figure of above-mentione...

Embodiment 3

[0249] Embodiment 3: Preparation of the crystallization (B crystal form) of the compound of formula I

[0250] (1) Dissolve 8 g of vortioxetine free base in toluene, add 0.95 equivalent of hydrobromic acid (47% hydrobromic acid aqueous solution), stir and crystallize, and filter the precipitate to obtain vortioxetine hydrobromic acid Salt (92%);

[0251] (2) Put 10 g of the product obtained in step (1) into a three-necked flask, add 120 g of toluene and 12 g of water, heat to 85 ° C and stir to dissolve, cool and crystallize, and dry the filtered crystals at a temperature of 60-70 ° C to obtain hydrogen Vortioxetine bromate (91%);

[0252] (3) Put 1 g of the product obtained in step (2) into a three-necked flask, add 15 g of acetone, stir at 55-60 ° C for 40 min to form a slurry, then stir at room temperature for 2 hours, filter, and vacuum-dry the obtained crystals to obtain It is a crystal of the B crystal form.

[0253] The powder X-ray diffraction figure of above-ment...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a hydrobromide of vortioxetine and in particular relates to a crystal of a compound shown in a formula I in the specification. The crystal uses Cu-K alpha radiation. In a powder X-ray diffraction pattern shown by a 2theta angle, diffraction peaks exist at about 6.89 degrees, 9.73 degrees, 13.78 degrees and 14.62 degrees. The invention also relates to a preparation method of the crystal and a drug composition containing the compound. The compound shows the serotonin reabsorption inhibitory activity, has activities towards a serotonin receptor 1A (5-HT1A) and a serotonin receptor 3 (5-HT3), can be used for treating the CNS (central nervous system)-related diseases, and in particular can be used for treating depressive disorder, especially major depressive disorder of adults.

Description

technical field [0001] The present invention relates to a compound which exhibits serotonin reuptake inhibitory activity, and which exhibits serotonin receptor 1A (5-HT 1A ) and serotonin receptor 3 (5-HT 3 ) has activity, and the compound can be used to treat CNS-related diseases. More specifically, the present invention relates to an inhibitor of 5-hydroxytryptamine transporter, which is a drug that can be used to treat depression, especially major depression in adults, and especially relates to a chemical name that can be called 1-[2 -(2,4-Dimethylphenylsulfanyl)phenyl]piperazine hydrobromide, more particularly to the crystallization of said drug. Background technique [0002] Selective serotonin reuptake inhibitors (SSRIs) have been the first-choice therapy for many years for the treatment of certain CNS-related disorders, notably depression, anxiety, and social phobia, due to differences from previously used compounds (ie , traditional tricyclic compounds), these inh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D295/096A61K31/495A61K47/26A61P25/00A61P25/24A61P25/28A61P25/18A61P35/00A61P25/16A61P25/22A61P29/00A61P25/30
CPCC07D295/096
Inventor 温光辉解卓峰付冀峰宛六一
Owner BEIJING LABWORLD BIO MEDICINE TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com